Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
SHILPAMEDNSEShilpa Medicare Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Wed, 14 May, 2025 · 20:42 IST

Shilpa Medicare Limited has informed the Exchange Shilpa Pharma Lifesciences Limited, Unit-1, Received EIR from USFDA

Regulatory & Legal View source PDFExplain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.4%Reaction day
₹348.00
prior close
₹350.60
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+1.4% vs market
Pharmaceuticals peers, median of 150sector+0.4%+2.1% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.7
10m
+1.7
15m
+3.1
30m
+2.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.4+1.0+1.4+0.4+2.1
Next day
+1.3+1.8-0.5+0.8+0.5
2d
+2.6+3.0-0.4+1.8+0.7
3d
+1.1+1.9-0.8+1.2-0.1
4d
+1.0+2.7-1.7+1.9-0.9
5d
+6.0+2.6+3.5+1.8+4.2
1w
+27.2+3.8+23.4+1.7+25.6
15d
+30.1+5.7+24.4+2.6+27.4
1m
+42.2+6.7+35.6+2.6+39.7
2m
+29.1+9.6+19.6+4.8+24.4
3m
+28.6+4.6+24.0+0.0+28.6
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Pharma Lifesciences Limited, Unit-1, a facility associated with Shilpa Medicare Limited, has received an Establishment Inspection Report (EIR) from the US FDA. An EIR is issued by the US FDA after it closes out an inspection of a manufacturing facility, generally indicating that the inspection has been concluded without any further regulatory action. The development signals regulatory clearance for the unit from the US drug regulator.

Likely market impact

This is a positive update for shareholders as it removes any lingering regulatory uncertainty around Unit-1, supporting uninterrupted supplies to the US market and potentially easing investor concerns about compliance issues.